Evidence map›Paper›PMID 39574477›Full record

ArticleOncology research2024

Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through

Weitao Zheng, Dong Jiang, Songen Chen, Meiling Wu, Baoqi Yan, Jiahui Zhai, Yunqiang Shi, Bin Xie, Xingwang Xie, Kanghong Hu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Landscape ofMolecular therapy. Methods & clinical development · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Weitao ZhengSino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education of China & Hubei Province), Hubei University of Technology, Wuhan, 430068, China.
Dong JiangCenter of Research & Development, Beijing CorreGene Biotechnology Co., Ltd., Beijing, 102206, China.
Songen ChenSino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education of China & Hubei Province), Hubei University of Technology, Wuhan, 430068, China.
Meiling WuSino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education of China & Hubei Province), Hubei University of Technology, Wuhan, 430068, China.
Baoqi YanCenter of Research & Development, Beijing CorreGene Biotechnology Co., Ltd., Beijing, 102206, China.
Jiahui ZhaiCenter of Research & Development, Beijing CorreGene Biotechnology Co., Ltd., Beijing, 102206, China.
Yunqiang ShiCenter of Research & Development, Beijing CorreGene Biotechnology Co., Ltd., Beijing, 102206, China.
Bin XieSino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education of China & Hubei Province), Hubei University of Technology, Wuhan, 430068, China.
Xingwang XieCenter of Research & Development, Beijing CorreGene Biotechnology Co., Ltd., Beijing, 102206, China.
Kanghong HuSino-German Biomedical Center, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Cooperative Innovation Center of Industrial Fermentation (Ministry of Education of China & Hubei Province), Hubei University of Technology, Wuhan, 430068, China.
Wenxue MaDepartment of Medicine, Sanford Stem Cell Institute and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The Kirsten rat sarcoma virus (KRAS) G12D oncogenic mutation poses a significant challenge in treating solid tumors due to the lack of specific and effective therapeutic interventions. This study aims to explore innovative approaches in T cell receptor (TCR) engineering and characterization to target the KRAS G12D Methods: In this innovative study, we engineered and characterized two T cell receptors (TCRs), KDA11-01 and KDA11-02 with high affinity for the KRAS G12D Results: KDA11-01 and KDA11-02 demonstrated exceptional specificity for the HLA-A*11:01-restricted KRAS G12D Conclusions: The successful development of KDA11-01 and KDA11-02 introduces a novel and precise TCR-based therapeutic strategy against KRAS G12D mutation, showing potential for significant advancements in cancer immunotherapy.

Indexed as

MutationNeoplasmsProto-Oncogene Proteins p21(ras)Receptors, Antigen, T-CellCell Line, TumorHumansImmunotherapyLymphocytes, Tumor-InfiltratingKRAS protein, humanProto-Oncogene Proteins p21(ras)Receptors, Antigen, T-CellAlloreactivityG12DKirsten rat sarcoma virus (KRAS)T cell receptor (TCR)TCR therapyTumor-infiltrating lymphocytes (TILs)

Identifiers

PMID39574477
PMCPMC11576958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.